Karen E Weck

List of Publications by Year
in descending order

68 papers	3,612 citations	126858 33 h-index	138417 58 g-index
70 all docs	70 docs citations	70 times ranked	5165 citing authors

#	Article	IF	Citations
1	Verifying nomenclature of DNA variants in submitted manuscripts: Guidance for journals. Human Mutation, 2021, 42, 3-7.	1.1	10
2	Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotypeâ€Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Clinical Pharmacology and Therapeutics, 2021, 109, 705-715.	2.3	25
3	Effects of aging on clinical outcomes in patients receiving genotypeâ€guided P2Y12 inhibitor selection after percutaneous coronary intervention. Pharmacotherapy, 2021, , .	1.2	3
4	Recommendations for Clinical CYP2D6 Genotyping Allele Selection. Journal of Molecular Diagnostics, 2021, 23, 1047-1064.	1.2	73
5	The Role of Clinical Laboratories in Emerging Pathogensâ€"Insights From the COVID-19 Pandemic. JAMA Health Forum, 2021, 2, e213154.	1.0	2
6	Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. Genetics in Medicine, 2020, 22, 160-169.	1.1	41
7	Genomic Sequencing for Newborn Screening: Results of the NC NEXUS Project. American Journal of Human Genetics, 2020, 107, 596-611.	2.6	63
8	Effect of Gender on Clinical Outcomes in Patients Receiving CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation Genomic and Precision Medicine, 2020, 13, 554-556.	1.6	2
9	Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients. Pharmacogenomics, 2020, 21, 431-441.	0.6	7
10	Recommendations for Clinical Warfarin Genotyping Allele Selection. Journal of Molecular Diagnostics, 2020, 22, 847-859.	1.2	39
11	Assessing the implications of positive genomic screening results. Personalized Medicine, 2020, 17, 101-109.	0.8	6
12	Genotype and Phenotype Concordance for Pharmacogenetic Tests Through Proficiency Survey Testing. Archives of Pathology and Laboratory Medicine, 2020, 144, 1057-1066.	1.2	5
13	An approach to integrating exome sequencing for fetal structural anomalies into clinical practice. Genetics in Medicine, 2020, 22, 954-961.	1.1	49
14	Recommendations for Clinical CYP2C9 Genotyping Allele Selection. Journal of Molecular Diagnostics, 2019, 21, 746-755.	1.2	84
15	CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention. Circulation Genomic and Precision Medicine, 2019, 12, e002441.	1.6	10
16	Recommendations for Clinical CYP2C19 Genotyping Allele Selection. Journal of Molecular Diagnostics, 2018, 20, 269-276.	1.2	131
17	Interpretation of genomic sequencing: variants should be considered uncertain until proven guilty. Genetics in Medicine, 2018, 20, 291-293.	1.1	23
18	CAP/ACMG proficiency testing for biochemical genetics laboratories: a summary of performance. Genetics in Medicine, 2018, 20, 83-90.	1.1	7

#	Article	IF	Citations
19	Multisite Investigation of Outcomes WithÂImplementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 181-191.	1.1	213
20	â€œPossibly positive or certainly uncertain?â€¦ participantsâ€™ responses to uncertain diagnostic results from exome sequencing. Genetics in Medicine, 2018, 20, 313-319.	1.1	39
21	The prevalence of the defining features of primary ciliary dyskinesia within a cri du chat syndrome cohort. Pediatric Pulmonology, 2018, 53, 1565-1573.	1.0	4
22	Combination of exome sequencing and immune testing confirms Aicardiâ€“GoutiÃ¨res syndrome type 5 in a challenging pediatric neurology case. Journal of Physical Education and Sports Management, 2018, 4, a002758.	0.5	6
23	The Next Generation of Molecular Pathology is Here: Validation of Next-Generation Sequencing Technology for Clinical Molecular Testing Across Multiple Different Disciplines. Archives of Pathology and Laboratory Medicine, 2017, 141, 749-750.	1.2	1
24	Whole Exome Sequencing Identifies Truncating Variants in Nuclear Envelope Genes in Patients With Cardiovascular Disease. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	34
25	Development and Validation of Targeted Next-Generation Sequencing Panels for Detection of Germline Variants in Inherited Diseases. Archives of Pathology and Laboratory Medicine, 2017, 141, 787-797.	1.2	35
26	Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment. Pharmacogenetics and Genomics, 2017, 27, 402-409.	0.7	14
27	A survey of current practices for genomic sequencing test interpretation and reporting processes in US laboratories. Genetics in Medicine, 2017, 19, 575-582.	1.1	68
28	Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. Oncologist, 2016, 21, 795-803.	1.9	42
29	Highly accurate molecular genetic testing for HFE hereditary hemochromatosis: results from 10 years of blinded proficiency surveys by the College of American Pathologists. Genetics in Medicine, 2016, 18, 1206-1213.	1.1	5
30	A panoramic view of the accuracy of molecular genetic testing. Genetics in Medicine, 2016, 18, 1188-1189.	1.1	1
31	<scp>FNA</scp> smears as a potential source of <scp>DNA</scp> for targeted nextâ€generation sequencing of lung adenocarcinomas. Cancer Cytopathology, 2016, 124, 406-414.	1.4	61
32	A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing. Genetics in Medicine, 2016, 18, 467-475.	1.1	74
33	In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. British Journal of Clinical Pharmacology, 2015, 80, 1122-1130.	1.1	40
34	Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC. PLoS ONE, 2015, 10, e0129280.	1.1	36
35	High Diagnostic Yield of Whole Exome Sequencing in Participants With Retinal Dystrophies in a Clinical Ophthalmology Setting. American Journal of Ophthalmology, 2015, 160, 354-363.e9.	1.7	27
36	The phenotype of multiple congenital anomaliesâ€hypotoniaâ€seizures syndrome 1: Report and review. American Journal of Medical Genetics, Part A, 2015, 167, 2176-2181.	0.7	24

#	Article	IF	Citations
37	Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. Pharmacogenomics, 2015, 16, 303-313.	0.6	32
38	CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 1231-1242.	2.2	73
39	Molecular genetic testing for cystic fibrosis: laboratory performance on the College of American Pathologists external proficiency surveys. Genetics in Medicine, 2015, 17, 219-225.	1.1	13
40	Podocyte-associated gene mutation screening in a heterogeneous cohort of patients with sporadic focal segmental glomerulosclerosis. Nephrology Dialysis Transplantation, 2014, 29, 2062-2069.	0.4	29
41	Cri du Chat Syndrome and Primary Ciliary Dyskinesia: A Common Genetic Cause on Chromosome 5p. Journal of Pediatrics, 2014, 165, 858-861.	0.9	15
42	Methods-Based Proficiency Testing in Molecular Genetic Pathology. Journal of Molecular Diagnostics, 2014, 16, 283-287.	1.2	49
43	A novel TRPC6mutation in a family with podocytopathy and clinical variability. BMC Nephrology, 2013, 14, 104.	0.8	23
44	A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record. Genetics in Medicine, 2013, 15, 824-832.	1.1	62
45	Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet, The, 2013, 382, 790-796.	6.3	237
46	Molecular genetic testing for fragile X syndrome: laboratory performance on the College of American Pathologists proficiency surveys (2001â€“2009). Genetics in Medicine, 2012, 14, 306-312.	1.1	22
47	Design and Analytical Validation of Clinical DNA Sequencing Assays. Archives of Pathology and Laboratory Medicine, 2012, 136, 41-46.	1.2	35
48	Verification of Performance Specifications of a Molecular Test: Cystic Fibrosis Carrier Testing Using the Luminex Liquid Bead Array. Archives of Pathology and Laboratory Medicine, 2012, 136, 14-19.	1.2	7
49	Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements. Clinical Cancer Research, 2012, 18, 2056-2065.	3.2	141
50	Certification in Molecular Pathology in the United States. Journal of Molecular Diagnostics, 2012, 14, 541-549.	1.2	4
51	Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study. Journal of Clinical Oncology, 2011, 29, 3232-3239.	0.8	173
52	Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy. Radiation Oncology, 2011, 6, 114.	1.2	26
53	Next generation massively parallel sequencing of targeted exomes to identify genetic mutations in primary ciliary dyskinesia: Implications for application to clinical testing. Genetics in Medicine, 2011, 13, 218-229.	1.1	59
54	Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all. Expert Review of Molecular Diagnostics, 2010, 10, 329-351.	1.5	29

#	Article	IF	Citations
55	Sensorineural Hearing Loss in a Pediatric Population. JAMA Otolaryngology, 2010, 136, 999.	1.5	21
56	Institutional Profile: UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care. Pharmacogenomics, 2010, 11, 13-21.	0.6	1
57	Characterization of 107 Genomic DNA Reference Materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1. Journal of Molecular Diagnostics, 2010, 12, 835-846.	1.2	98
58	VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. Thrombosis Research, 2010, 126, e206-e210.	0.8	14
59	Validation of Clinical Testing for Warfarin Sensitivity. Journal of Molecular Diagnostics, 2009, 11, 216-225.	1.2	53
60	Role of the clinical laboratory in personalized medicine: challenges and opportunities. Personalized Medicine, 2008, 5, 1-4.	0.8	1
61	A multicenter study of the frequency and distribution of GJB2 and GJB6 mutations in a large North American cohort. Genetics in Medicine, 2007, 9, 413-426.	1.1	134
62	Murine Gammaherpesvirus 68 Infection Is Associated with Lymphoproliferative Disease and Lymphoma in BALB Î²2 Microglobulin-Deficient Mice. Journal of Virology, 2005, 79, 14668-14679.	1.5	98
63	Hepatitis C Virus Genotyping: Interrogation of the 5' Untranslated Region Cannot Accurately Distinguish Genotypes 1a and 1b. Journal of Clinical Microbiology, 2002, 40, 3127-3134.	1.8	111
64	New cytogenetic variant, insertion (15;17)(q22;q12q21), in an adolescent with acute promyelocytic leukemia. Cancer Genetics and Cytogenetics, 2002, 134, 55-59.	1.0	6
65	Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clinical Transplantation, 2002, 16, 92-96.	0.8	57
66	Macrophages Are the Major Reservoir of Latent Murine Gammaherpesvirus 68 in Peritoneal Cells. Journal of Virology, 1999, 73, 3273-3283.	1.5	271
67	B Cells Regulate Murine Gammaherpesvirus 68 Latency. Journal of Virology, 1999, 73, 4651-4661.	1.5	179
68	Murine Î³-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-Î³ responsiveness: A new model for virus-induced vascular disease. Nature Medicine, 1997, 3, 1346-1353.	15.2	230